Molecular characterization has led to the definition of new subgroups such as lung cancer mutated for epidermal growth factor receptor, lung cancer rearranged for analytic lymphoma kinase and ROS1 kinase domain, and PDL1 expression, which need specific treatments and strategies [2]. This evidence concerns the gene CD274 and lung carcinoma.